HK1079703A1 - 通過靜脈施用鹵化揮發性麻醉藥保護心臟和保護神經的方法 - Google Patents

通過靜脈施用鹵化揮發性麻醉藥保護心臟和保護神經的方法

Info

Publication number
HK1079703A1
HK1079703A1 HK05112083.8A HK05112083A HK1079703A1 HK 1079703 A1 HK1079703 A1 HK 1079703A1 HK 05112083 A HK05112083 A HK 05112083A HK 1079703 A1 HK1079703 A1 HK 1079703A1
Authority
HK
Hong Kong
Prior art keywords
cardioprotection
neuroprotection
intravenous administration
ischemic event
halogenated volatile
Prior art date
Application number
HK05112083.8A
Other languages
English (en)
Inventor
勞爾．特里洛
拉爾夫．萊瑟
薩蒂什．佩亞韋爾
納夫尼特．普里
Original Assignee
巴克斯特國際公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 巴克斯特國際公司 filed Critical 巴克斯特國際公司
Publication of HK1079703A1 publication Critical patent/HK1079703A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK05112083.8A 2002-10-11 2005-12-29 通過靜脈施用鹵化揮發性麻醉藥保護心臟和保護神經的方法 HK1079703A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41793402P 2002-10-11 2002-10-11
PCT/US2003/031826 WO2004032858A2 (en) 2002-10-11 2003-10-09 Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics

Publications (1)

Publication Number Publication Date
HK1079703A1 true HK1079703A1 (zh) 2006-04-13

Family

ID=32094122

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05112083.8A HK1079703A1 (zh) 2002-10-11 2005-12-29 通過靜脈施用鹵化揮發性麻醉藥保護心臟和保護神經的方法

Country Status (19)

Country Link
US (1) US7999011B2 (zh)
EP (1) EP1558226B1 (zh)
JP (1) JP5210486B2 (zh)
KR (2) KR20120030598A (zh)
CN (2) CN1703209A (zh)
AT (1) ATE546136T1 (zh)
AU (1) AU2003282464B2 (zh)
BR (1) BR0314617A (zh)
CA (1) CA2500310C (zh)
DK (1) DK1558226T3 (zh)
ES (1) ES2382911T3 (zh)
HK (1) HK1079703A1 (zh)
IL (1) IL167472A (zh)
MX (1) MXPA05003741A (zh)
NZ (1) NZ539298A (zh)
PL (1) PL219493B1 (zh)
RU (1) RU2350323C2 (zh)
WO (1) WO2004032858A2 (zh)
ZA (1) ZA200502741B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1429749A2 (en) 2001-09-26 2004-06-23 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
WO2008036858A2 (en) * 2006-09-20 2008-03-27 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
GB0619499D0 (en) 2006-10-03 2006-11-08 Lucent Technologies Inc Encrypted data in a wireless telecommunications system
DE112008002914A5 (de) * 2007-11-06 2010-09-30 B. Braun Melsungen Ag Einen hydrophoben Wirkstoff enthaltende wässrige Emulsionen
CA2712516C (en) * 2008-01-22 2016-06-28 Vapogenix, Inc. Volatile anesthetic compositions and methods of use
AU2015200210B2 (en) * 2008-01-22 2016-08-11 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
US9675544B2 (en) * 2008-01-22 2017-06-13 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
WO2010129686A1 (en) * 2009-05-05 2010-11-11 Vapogenix, Inc. Novel formulations of volatile anesthetics and methods of use for reducing inflammation
EP2459182B1 (en) * 2009-07-30 2017-09-06 University of Zürich Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event
FR2956323B1 (fr) * 2010-02-15 2013-12-20 Air Liquide Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques
CN107260670A (zh) 2011-06-24 2017-10-20 维普詹尼克斯公司 用于治疗皮肤病症或疾病的新型制剂和方法
CN113712911A (zh) 2013-03-15 2021-11-30 维普詹尼克斯公司 新型镇痛组合物
ITMO20130075A1 (it) * 2013-03-22 2014-09-23 Enrico Giuliani Dispositivo di somministrazione

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1018773A (en) * 1962-09-13 1966-02-02 Bellon Labor Sa Roger ª‡-phenyl-ª‰-2-furyl-propionitrile derivatives
US4073943A (en) 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US5628930A (en) 1992-10-27 1997-05-13 Alliance Pharmaceutical Corp. Stabilization of fluorocarbon emulsions
US5635538A (en) 1993-03-16 1997-06-03 Alliance Pharmaceutical Corp. Fluorocarbon emulsions with reduced pulmonary gas-trapping properties
JP2961034B2 (ja) * 1993-09-16 1999-10-12 アルプス電気株式会社 磁気ヘッド
ATE211135T1 (de) 1993-09-24 2002-01-15 Univ British Columbia Aminocyclohexylester und ihre anwendung
FR2726267B1 (fr) * 1994-10-26 1998-01-02 Smithkline Beecham Lab Nouveaux agents anti-arythmiques, compositions pharmaceutiques les contenant, et procede pour les preparer
GB2350297A (en) 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
IL154060A0 (en) 2000-07-26 2003-07-31 Taro Pharma Ind Mon-sedating barbiturate compounds as neuroprotective agents

Also Published As

Publication number Publication date
RU2350323C2 (ru) 2009-03-27
EP1558226A4 (en) 2008-04-02
CN102283821A (zh) 2011-12-21
ZA200502741B (en) 2006-02-22
JP5210486B2 (ja) 2013-06-12
ATE546136T1 (de) 2012-03-15
WO2004032858A3 (en) 2004-09-23
CN1703209A (zh) 2005-11-30
PL376217A1 (en) 2005-12-27
AU2003282464B2 (en) 2010-02-25
US20040127578A1 (en) 2004-07-01
JP2006504740A (ja) 2006-02-09
PL219493B1 (pl) 2015-05-29
EP1558226A2 (en) 2005-08-03
CA2500310C (en) 2013-03-12
CA2500310A1 (en) 2004-04-22
WO2004032858A2 (en) 2004-04-22
AU2003282464A1 (en) 2004-05-04
IL167472A (en) 2013-10-31
ES2382911T3 (es) 2012-06-14
DK1558226T3 (da) 2012-05-07
KR20120030598A (ko) 2012-03-28
BR0314617A (pt) 2005-08-02
MXPA05003741A (es) 2005-06-17
US7999011B2 (en) 2011-08-16
KR101403264B1 (ko) 2014-06-02
EP1558226B1 (en) 2012-02-22
NZ539298A (en) 2008-11-28
RU2005114008A (ru) 2005-10-27
KR20050056230A (ko) 2005-06-14

Similar Documents

Publication Publication Date Title
HK1079703A1 (zh) 通過靜脈施用鹵化揮發性麻醉藥保護心臟和保護神經的方法
RUBIN Intracordal injection of silicone in selected dysphonias
Podoshin et al. Effects of peritonsillar infiltration on post-tonsillectomy pain: a double-blind study
JP2001510795A5 (zh)
Jayakaran et al. Local anesthetics in pediatric dental practice
Alioto et al. Hematoma block for ankle fractures: a safe and efficacious technique for manipulations
ATE446309T1 (de) Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung
Kulkarni et al. Painless anaesthesia in pediatric dentistry: an updated review
Yaacob et al. The efficacy of xylocaine topical anaesthetic in reducing injection pain
WO2003015690B1 (en) Method for treating primary insomnia
LT2006024A (en) Tetrapeptide regulating blood glucose level in diabetes mellitus
Raja et al. Donor site analgesia after anterior iliac bone grafting in paediatric population: a prospective, triple-blind, randomized clinical trial
US20050176823A1 (en) Intra-operative procedure for post-operative pain control
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
Padmanabhan et al. Dental Anesthesia: Can Needle-Free Injections Help
UA27230C2 (uk) Похідні андростану, заміщені по 16-му положенню четвертинною амонієвою групою, для використання як нервово-м'язових блокаторів та фармацевтична композиція, що здатна викликати нервово-м'язову блокаду
US4017619A (en) Anesthetic and sedative composition
COŞAR et al. Pain control following lumbar laminectomy: Comparison of epidural morphine and morphine plus bupivacaine
Gupta et al. Intrathecal administration of bupivacaine and bupivacaine with different doses of clonidine for post-operative analgesia in lower abdominal and lower limb surgeries–A comparative study
Nagargoje et al. Recent advances in local anesthesia delivery systems: a review
Arangannal et al. Intranasal Local Anaesthesia: A Recent Advancement in Pediatric Dentistry.
Shazad et al. Comparison Between Topical and Intravenous Xylocaine on Pharyngo-Laryngeal Complications in Breast Surgery Patients
Bavisha et al. Comparison of patient-controlled and operator-controlled conscious sedation for restorative dentistry
WANGEMAN Methohexital sodium
Goodman et al. Subcutaneous bupivacaine for treatment of spasticity: A case report